Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Black Diamond Therapeutics Inc

Healthcare US BDTX

2.155USD
0.06(2.62%)

Last update at 2026-06-04T18:15:00Z

Day Range

2.072.21
LowHigh

52 Week Range

1.464.94
LowHigh

Fundamentals

  • Previous Close 2.10
  • Market Cap180.46M
  • Volume393154
  • P/E Ratio8.08
  • Dividend Yield-%
  • EBITDA20.20M
  • Revenue TTM70.00M
  • Revenue Per Share TTM1.23
  • Gross Profit TTM 70.00M
  • Diluted EPS TTM0.39

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 22.37M -69.67600M -82.44200M -88.91900M -125.59600M
Minority interest - - - - -
Net income 22.37M -69.67600M -82.44200M -84.52000M -123.20300M
Selling general administrative 16.57M 27.47M 27.11M 28.39M 30.04M
Selling and marketing expenses - - 27.08M - -
Gross profit 69.67M -0.34300M -0.43700M - -
Reconciled depreciation 0.33M 0.34M 0.44M 0.51M 0.20M
Ebit 19.87M -78.78100M -86.46000M -92.82800M -126.87200M
Ebitda 20.20M -78.43800M -86.02300M -95.06000M -125.59600M
Depreciation and amortization 0.33M 0.34M 0.44M -2.23200M 1.28M
Non operating income net other - - - 1.66M 1.28M
Operating income 19.87M -78.78100M -86.46000M -92.82800M -126.87200M
Other operating expenses 50.13M 78.78M 86.46M 92.83M 126.87M
Interest expense - - - -3.90900M 1.28M
Tax provision - - - - -
Interest income 4.06M 2.18M 1.92M 2.03M 3.46M
Net interest income 4.06M 2.18M 1.92M 2.03M 3.46M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -4.39900M -2.39300M
Total revenue 70.00M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 49.80M 78.78M 86.02M 92.83M 126.87M
Cost of revenue 0.33M 0.34M 0.44M - -
Total other income expense net 2.50M 9.11M 4.02M 3.91M 1.28M
Discontinued operations - - - - -
Net income from continuing ops 22.37M -69.67600M -82.44200M -91.16900M -125.59600M
Net income applicable to common shares - - - -91.16900M -125.59600M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 143.01M 122.64M 158.57M 156.25M 247.68M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.79M 2.60M 2.63M 4.90M 5.92M
Total liab 30.80M 39.35M 41.83M 40.56M 491.50M
Total stockholder equity 112.21M 83.28M 116.74M -334.98900M -243.82000M
Deferred long term liab - - - - -
Other current liab 15.15M 13.16M 14.21M 10.54M 19.21M
Common stock 0.00800M 0.00700M 0.00700M 0.00500M 0.00500M
Capital stock 0.00800M 0.00700M 0.00700M 0.00500M 0.00500M
Retained earnings -464.74000M -487.10700M -417.43100M -334.98900M -243.82000M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M 1.17M 1.24M
Cash 20.99M 36.44M 56.22M 34.31M 65.80M
Cash and equivalents - - - - -
Total current liabilities 15.73M 20.57M 19.65M 15.26M 23.64M
Current deferred revenue - - - - -
Net debt -5.92200M -14.25100M -30.92300M -6.17500M -37.33900M
Short term debt - 3.40M 3.11M 2.84M 0.32M
Short long term debt - - - - -
Short long term debt total 15.07M 22.19M 25.30M 28.14M 28.46M
Other stockholder equity 576.84M 570.36M 534.19M 1.82M 0.41M
Property plant equipment - - - 2.59M 30.74M
Total current assets 132.44M 101.18M 134.03M 127.71M 209.79M
Long term investments - - - - -
Net tangible assets - - - 115.69M 195.90M
Short term investments 107.66M 62.14M 75.18M 88.49M 143.99M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.58M 4.01M 2.32M 1.88M 4.11M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.10M 0.02M -0.02700M -1.82400M -0.41400M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00500M 0.00500M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -334.98900M -243.82000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.07M 1.07M 0.82M 1.17M 7.16M
Deferred long term asset charges - - - - -
Non current assets total 10.57M 21.46M 24.53M 28.55M 37.90M
Capital lease obligations 18.78M 22.19M 25.30M 28.14M 28.46M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -44.93200M 16.97M 16.35M 53.55M 133.32M
Change to liabilities - - - -8.09400M 1.57M
Total cashflows from investing activities -44.90500M 16.97M 16.35M 53.37M 130.61M
Net borrowings - - - - -
Total cash from financing activities -0.14600M 25.55M 71.93M 0.18M 0.73M
Change to operating activities - - - -7.67100M 5.45M
Net income 22.37M -69.67600M -82.44200M -91.16900M -125.59600M
Change in cash -15.43700M -19.78800M 21.56M -31.53900M 31.19M
Begin period cash flow 37.26M 57.04M 35.48M 67.02M 35.83M
End period cash flow 21.82M 37.26M 57.04M 35.48M 67.02M
Total cash from operating activities 29.61M -62.30300M -66.71700M -85.08200M -100.14800M
Issuance of capital stock 0.00000M 24.49M 71.85M - 0.00000M
Depreciation 0.33M 0.34M 0.44M 0.51M 0.20M
Other cashflows from investing activities 0.07M 0.09M 0.10M 0.00900M -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - 0.18M 0.73M
Other cashflows from financing activities -0.14600M 1.05M 0.08M 53.37M 0.73M
Change to netincome - - - 12.21M 18.22M
Capital expenditures 0.00000M 0.00000M 0.03M 0.19M 2.71M
Change receivables - - - - -
Cash flows other operating - - - 0.92M -1.26100M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -31.53900M 31.19M
Change in working capital -8.72800M -2.69200M 3.69M -9.90100M 7.02M
Stock based compensation 6.63M 10.63M 9.60M 12.20M 14.04M
Other non cash items 9.02M -0.90500M 2.00M 3.28M 2.01M
Free cash flow 29.61M -62.30300M -66.75000M -85.27400M -102.85800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BDTX
Black Diamond Therapeutics Inc		 0.06 2.62% 2.15 8.08 8.33 2.58 1.56 0.93 3.21
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics Inc

245 First Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Dr. David M. Epstein Ph.D. Co-Founder, Pres, CEO & Director 1959
Dr. Fang Ni Pharm.D. CFO, Principal Financial Officer and Chief Bus. Officer 1987
Mr. Brent Hatzis-Schoch Esq., J.D. COO & Gen. Counsel 1965
Dr. Elizabeth Buck Ph.D. Co-Founder & Chief Scientific Officer 1975
Ms. Erika Jones VP of Fin., Corp. Controller & Principal Accounting Officer 1985
Ms. Elizabeth L. Montgomery Chief People Officer 1972
Dr. Christopher D. Roberts Ph.D. Advisor 1970
Mr. Tai-An Lin Ph.D. Sr. VP of Translational Science & Discovery Biology NA
Dr. Sergey Yurasov M.D., Ph.D. Chief Medical Officer 1969
Ms. Melanie Morrison Sr. VP of Devel. Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.